BATON ROUGE, LA – We are proud to recognize Dr. Ira Thorla, a principal investigator at Louisiana Dermatology Associates, for successfully completing enrollment in a Phase 2 urticaria clinical trial and delivering exceptional performance from start to finish.

Dr. Thorla exceeded expectations by enrolling 300% of the study enrollment target, a remarkable achievement that reflects both his deep community engagement and the operational readiness of his research team. This success is especially impressive given the complex nature of urticaria studies, which often require detailed screening and careful patient management.

In addition to surpassing enrollment goals, Dr. Thorla supported a rapid site activation timeline, becoming fully operational just 41 days after the study was awarded. This quick turnaround enabled early patient access to the investigational treatment and accelerated trial progress for the sponsor.

Dr. Thorla’s contributions extended beyond his own site; he was responsible for enrolling over 20% of the study’s total patient population, underscoring the scale and impact of his efforts within the broader trial.

With more than 50 clinical trials completed in partnership with DelRicht Research, Dr. Thorla continues to demonstrate the qualities of a trusted investigator: efficiency, expertise, and a strong commitment to patient-centered research. His leadership helps ensure that new therapies are brought to market faster and with broader representation.

Thank you, Dr. Ira Thorla, for your continued dedication to advancing care for patients with chronic dermatologic conditions. Your work is making a real difference in the lives of those affected by urticaria.